Following  the  discontinuation  of  TACTI 004,  a  payment  obligation  has  arisen  under  the Companys licence agreement with Dr. Reddys. Under the licence agreement terms, the Company must pay US$10 million to Dr. Reddys by June 2026 in these circumstances. No payment has been made to Dr. Reddys at the date of this announcement. The expected payment  will  result  in  a  cash  outflow  of  US$10  million  in  the  June  2026  quarter  and corresponding reduction in unearned revenue.

The remaining balance of US$7.3 million in unearned  revenue is  expected to be  recognised as revenue  for the half-year  ending  30 June 2026.

/immutep-quarterly-activities-report-

Appendix 4C cash flow and estimated Cash:

Thursday Close:

receives-fda-odd-for-efti-in-soft-tissue

CEO of Immutep, Marc Voigt said: “We are pleased that the FDA has recognised the potential of efti for patients with soft tissue sarcoma, a rare and difficult to treat cancer

Return (inc div)   1yr: -77.96%   3yr: -39.09% pa   5yr: -34.38% pa

on todays announcement

Trades at 0.055cps

up 0.016cps

Up today 41%

The company's CEO, Marc Voigt, said: "We are very disappointed and surprised with the outcome of the futility analysis, in light of efti's performance in every other clinical trial. […] We are currently conducting a comprehensive review of the available data to better understand the results and determine the appropriate next steps for the program."

Immutep Limited (ASX: IMM) – Trading Halt Trading in the securities of Immutep Limited (‘IMM’) will be halted at the request of IMM, pending the release of an announcement by IMM. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of: • the commencement of normal trading on Wednesday, 11 March 2026; or • the release of the announcement to the market. IMM’s request for a trading halt is attached below for the information of the market. Issued by ASX Compliance

https://www.marketindex.com.au/asx/imm?src=search-all

IMM - Holders had 7 days 6th till 13th Mar then Bang the shares slide down the 'elevator'.. So speculators lost their shirts there.

Return (inc div)   1yr: -84.21%   3yr: -44.16% pa   5yr: -32.73% pa

Microcap $66Mill

No profit organisation!

please visit www.immutep.com.

IMM still has a pipeline of trials..

threads/ann-immutep-quarterly-act

• Release Date: 29/01/26 11:36
• Summary: Immutep Quarterly Activities Report and Appendix 4C
• IMM Estimate 7.7 quarters of funding. here:
•